Panbela Therapeutics (STU:X70) LT-Debt-to-Total-Asset : 0.30 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Panbela Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Panbela Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.30.

Panbela Therapeutics's long-term debt to total assets ratio increased from Mar. 2023 (0.26) to Mar. 2024 (0.30). It may suggest that Panbela Therapeutics is progressively becoming more dependent on debt to grow their business.

Panbela Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Panbela Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panbela Therapeutics LT-Debt-to-Total-Asset Chart

Panbela Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

1.04

0.36

Panbela Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.26	0.22	0.40	0.36	0.30

Panbela Therapeutics LT-Debt-to-Total-Asset Calculation

Panbela Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	3.846	/	10.822
	=

Panbela Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	2.938	/	9.685
	=

Panbela Therapeutics (STU:X70) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Panbela Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Panbela Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Panbela Therapeutics (STU:X70) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panbela Therapeutics Inc (STU:X70) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

PBLA:USA

Address

712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387

Website

https://www.panbela.com

Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.

Panbela Therapeutics (STU:X70) Headlines

No Headlines